Edwards Lifesciences Corporation (EW): Q3 2025 Earnings Snapshot
Headline Metrics
Key capital efficiency signals from Q3 2025 earnings.
Capital Efficiency Analysis
Revenue for Q3 2025 reached $1.55 billion, increasing 12.6% year-over-year, driven by strong sales in TAVR, which totaled $1.15 billion, up 10.6%. The TMTT product group saw remarkable growth, with sales rising 53% to $144 million, attributed to PASCAL and EVOQUE's performance. Adjusted gross profit margin decreased to 77.9%, down from 80.7% in the prior year, primarily due to foreign exchange impacts and rising operational expenses. Management raised full-year sales growth guidance to the high end of the previous 9% to 10% range and increased EPS guidance to between $2.56 and $2.62, reflecting confidence in ongoing growth drivers. Share repurchases exceeded $800 million year-to-date, with $2 billion remaining under the current authorization.
Capital Efficiency Trends
Capital Allocation Summary
$0.5 billion in cash deployment includes $0.2 billion for share buybacks and $0.1 billion for capital expenditures. No funds were allocated for dividends, acquisitions, or debt repayment.
Capital Allocation
Bottom Line
Edwards Lifesciences Corporation's ROIC increased by 31 basis points year-over-year to 15.9%. The company's FCF conversion saw a significant rise of 152.3 percentage points year-over-year, reaching 177.3%. Both metrics indicate improved capital efficiency for the company in Q3 2025.
Want More Capital Efficiency Analysis?
Get weekly insights on S&P 500 companies with standout ROIC and FCF performance.
Sign Up for FreeDisclaimer: This presentation is for informational and educational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any security or financial product. The information presented is based on publicly available financial data and should not be relied upon as the sole basis for investment decisions. Past performance is not indicative of future results. All investments carry risk, including the potential loss of principal. Readers should conduct their own research and consult with a qualified financial advisor before making any investment decisions. Valuestock.ai and its affiliates make no representations or warranties regarding the accuracy, completeness, or timeliness of the information presented.
